Blood markers may unlock early ALS detection — a study puts them to the test

NCT ID NCT07737977

Not yet recruiting Knowledge-focused Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

ALS is a progressive nerve disease with no simple test for early diagnosis or tracking. This study is collecting blood samples and medical data from 200 people with ALS to look for patterns in proteins, genes, and immune markers. The goal is to build a biomarker panel that could one day help doctors diagnose ALS sooner and predict how the disease will progress.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a blood test that helps diagnose ALS earlier and predict how the disease will progress.
What could go wrong: This is an observational study, not a treatment trial. It may not identify a useful biomarker panel, and results may take years to apply in clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALS - AMYOTROPHIC LATERAL SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis disease Disease Progression motor neuron disorder Nerve Degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALS - AMYOTROPHIC LATERAL SCLEROSIS

Contacts and locations

Locations

Hospital Universitari Vall D'Hebron

Barcelona, 08035, Spain
Montpellier University Hospital

Montpellier, Occitanie, 34295, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.